Category Archives: Antonella Tosti

Hair Rejuvenation versus Hair Cloning

A very interesting article that explores the difference between hair rejuvenation and hair cloning (or hair multiplication) was published yesterday. The interview itself took place “a little while ago”.

The article author interviewed Dr. Bessam Farjo (highly optimistic), Dr. Sara Wasserbauer (optimistic) and Dr. Antonella Tosti (more cautious). Both Dr. Farjo and Dr. Wasserbauer are associated with HairClone (UK), who I have covered on this blog since 2016. This company is scheduled to begin its “cell expansion services” in 2022.

See the below video for CEO Dr. Paul Kemp’s last update from 2021. I will likely be interviewing him later this year for a second time.

Edit: A 2009 paper from Intercytex scientists was titled: “Hair follicle neogenesis induced by cultured human scalp dermal papilla cells“. It has Dr. Kemp as a co-author since he was the CEO of Intercytex at the time.

Currently, HairClone is only banking your hair follicles for future cell cloning. If you are in the US, you can check out Dr. Wasserbauer’s site for more details on the follicle banking services.

Hair Rejuvenation of Dermal Papilla Cells versus Hair Cloning

What I find interesting in this article is that for the first time that I can recall, a  clear distinction is made between hair cloning and hair rejuvenation. The latter is undertaken via the “hair cloning” of dermal papillae and injection into thinning scalps.

According to Dr. Sara Wasserbauer, actual hair cloning (i.e. making a brand new follicle in the lab that then regenerates itself in a regular hair cycle) is still 10-20 year away. However:

“What is imminent is the cloning of dermal papillae cells, which serves to thicken existing thinning hair.”

Dr. Wasserbauer is discussing Hairclone’s technology here. Some would still call the replication of dermal papilla cells in the lab to be hair cloning or hair multiplication. However, in this article, they imply a better phrase to be “hair rejuvenation” or even “hair regeneration”.

  • Dr. Farjo (UK) thinks that HairClone’s procedure could be available to patients as early as the end of 2022/beginning of 2023.
  • Dr. Wasserbauer (US) thinks 2025/2026 is more likely, “barring any further Covid-related delays”.

However, Dr. Tosti seems skeptical:

Some experts, however, doubt the imminence of this technology. “The idea is there — to introduce stem cells into the follicle to increase the population of dermal papillae in order to grow thicker hair — but this is not happening right now,” says Dr. Tosti. “The published papers didn’t show that. It’s far from being close in clinical studies.”

One caveat is that the UK has favorable regulations that I have mentioned several times in the past. So this autologous cell injection procedure can be tested on patients in clinical settings under doctor supervision. With no published papers or clinical trials necessary.

According to the article, the most suitable candidates will be those who have not gone completely bald yet. It seems like even if you have some remaining hair in the permanent donor area, the procedure might be the wrong choice if you are completely bald in the rest of your scalp.

In general, you can expect significant thickening of existing thinning hair if HairClone’s procedure works. Perhaps they can improve on the results with more experience and also help Norwood 6 level bald men down the road?

Repeat Cell Injection Treatments Required

Note that HairClone’s procedure may be necessary up to three times over the course of a 10-year period. This is because male pattern hair loss and female pattern hair loss are both progressive conditions.

Because this procedure is not yet US FDA approved, the stem cell injections will initially have to take place in the UK. The FDA will possibly grant approval to store tissue at US storage facilities sometime in 2022.

The combined cost for banking, storage and injection will likely be on par with that of a hair transplant.

Encouraging Update on Polichem’s P-3074

In my popular post from last year regarding topical finasteride, I discussed Polichem’s P-3074 product. P-3074 is “vehicled” in Hydroxypropyl-Chitosan (HPCH) per the latest announcements. Past references state that it uses hydroxypropyl-chitosan (HPCH) as the “film-forming agent”.

Polichem: P-3074 Topical Finasteride Update

At this year’s just completed World Congress for Hair Research in Miami, one of the presentations pertained to this very product. The key quote from the abstract book:

“A pharmacokinetic phase I study, tested P-3074 b.i.d. [=twice per day] vs oral finasteride 1 mg o.d. [=once per day], revealing a finasteride systemic exposure 15 times lower in the topical formulation. A pharmacodynamic study compared P-3074 b.i.d. and o.d. vs oral finasteride 1 mg o.d. in DHT inhibition in scalp (vertex) and in serum. The results showed comparable serum/scalp DHT inhibitions across formulations, suggesting that the achievement of comparable levels of DHT inhibition vs the oral form could be attained by a lower dose of P-3074.”

My note: Their older report from the 7th World Congress for Hair Research from two years ago stated that the P-3074 product is composed of 0.25% finasteride. So the twice per day dose equals 0.50% per day. This is apparently lower than 1 mg/day oral finasteride per the implication of the last sentence in the above paragraph.

My note: They also state in the most recent abstract that at lower doses of 200 mcL, scalp DHT reduction remains unchanged. However, serum DHT reduction was much lower, potentially even further limiting systemic absorption. So 200mcL< 0.50% < 1mg. Currently, P-3074 is in Phase III clinical trials in Europe.

I called my local compounding pharmacy a few months ago to inquire about them making topical finasteride for me. They told me that while they do make topical finasteride in gel form, they only get several such requests each year. Moreover, at around $100 per month, it is much more expensive than the cost of generic oral finasteride.

What I am really looking forward to is a topical dutasteride product with very low systemic absorption. The results from oral dutasteride are clearly superior to those from oral finasteride. Make sure to read the comments to my dutasteride (Avodart) for hair loss user experiences post.

Unfortunately, oral dutasteride also results in significantly higher rates of side effects. We really need a topical version of dutasteride asap. Perhaps this will only happen after dutasteride is officially approved to treat hair loss.


Dr. Antonella Tosti is listed as a consultant to both Polichem and Kythera in the abstract I mentioned earlier.